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Abstract
Numerous studies have suggested a role for natural killer (NK) cells in attenuation of HIV-1 disease progression via
recognition by killer-cell immunoglobulin-like receptors (KIRs) of specific HLA class I molecules. The role of KIR and HLA class
I has not been addressed in the context of maternal-infant HIV-1 transmission. KIR and HLA class I B and C genes from 224
HIV-1-infected mothers and 222 infants (72 infected and 150 uninfected) from South Africa were characterized. Although a
number of significant associations were determined in both the total group and in the nevirapine (NVP) exposed group, the
most significant findings involved KIR2DL2 and KIR2DL3 and HLA-C. KIR2DL2/KIR2DL3 was underrepresented in intrapartum
(IP)-transmitting mothers compared to non-transmitting (NT) mothers (P=0.008) and remained significant (P=0.036) after
correction for maternal viral load (MVL). Homozygosity for KIR2DL3 alone and in combination with HLA-C allotype
heterozygosity (C1C2) was elevated in IP-transmitting mothers compared to NT mothers (P=0.034 and P=0.01 respectively),
and after MVL correction (P=0.033 and P=0.027, respectively). In infants, KIR2DL3 in combination with its HLA-C1 ligand
(C1) as well as homozygosity for KIR2DL3 with C1C2, were both found to be underrepresented in infected infants compared
to exposed uninfected infants in the total group (P=0.06 and P=0.038, respectively) and in the sub-group of infants whose
mothers received NVP (P=0.007 and P=0.03, respectively). These associations were stronger post MVL adjustment (total
group: P=0.02 and P=0.009, respectively; NVP group: P=0.004 and P=0.02, respectively). Upon stratification according to
low and high MVL, all significant associations fell within the low MVL group, suggesting that with low viral load, the effects
of genotype can be more easily detected. In conclusion this study has identified a number of significant associations that
suggest an important role for NK cells in maternal-to-infant HIV-1 transmission.
Citation: Paximadis M, Minevich G, Winchester R, Schramm DB, Gray GE, et al. (2011) KIR-HLA and Maternal-Infant HIV-1 Transmission in Sub-Saharan Africa. PLoS
ONE 6(2): e16541. doi:10.1371/journal.pone.0016541
Editor: Johan Sandberg, Karolinska Institutet, Sweden
Received September 6, 2010; Accepted January 2, 2011; Published February 4, 2011
Copyright:  2011 Paximadis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from NICHD 42402, the Wellcome Trust and Elizabeth Glaser Pediatric AIDS Foundation. Caroline T. Tiemessen is a
Wellcome Trust International Senior Research Fellow (076352/Z/05/Z). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: paxim@nicd.ac.za
Introduction
Natural killer (NK) cells, large bone marrow-derived granular
lymphocytes, are classically defined as playing an integral role in
the innate immune response by targeting virally-infected cells and
transformed cells with direct killing. In addition, they are known to
be involved in the adaptive immune response by providing help
through cytokine secretion. Increasingly however, the role of NK
cells in viral control is looking more complex. A mouse model of
cytomegalovirus infection has shown NK cells to display ‘memory’
features typical of an adaptive immune response [1]. NK cells have
also been shown to respond with marked specificity to HIV-1
peptides as measured by a whole blood intracellular cytokine assay
[2,3,4].
NK cell function is facilitated by a repertoire of receptors that
are encoded by several gene families, amongst which are the killer
immunoglobulin(Ig)-like receptor (KIR) genes that are located on
chromosome 19q13.4 and encode both activating and inhibitory
KIR receptors (see review: [5]). Expression of KIR receptors is
complex and controlled by a stochastic mechanism that shuts off
expression of some receptors and not others in individual cells
thereby allowing different NK cell clones to recognize their targets
differentially (see review: [6]). In addition, there is a high degree of
polymorphism in the KIR gene family and differences among
individuals with regard to KIR gene haplotypes that vary in
number and types of genes present [7,8]. The KIR receptors are
type I integral membrane glycoproteins that are usually expressed
on the cell surface as monomers and 14 distinct KIR genes and two
pseudogenes have been described to date (see http://www.ebi.ac.
uk/kir for latest updates on KIR genes and alleles). The KIR
receptors are named according to the number (i.e. 2 or 3) of Ig-like
domains present in the extracellular region as well as the length
(i.e. L: long or S: short) of their cytoplasmic tails. KIR receptors
can be divided into two broad groups based on function i.e. either
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munoreceptor tyrosine-based inhibition motifs (ITIMs) in these
domains] or activating [characterized by S cytoplasmic domains
with immunoreceptor tyrosine-based activation motifs (ITAMs) in
these domains] (see review: [9]). The ligands for KIR receptors for
the most part are the HLA class I molecules [10].
Increasingly, the part that NK cells play in the control of HIV-1
infection is being investigated with many genetic association
studies of the role of select KIR receptors in isolation, or in
combination with their HLA ligands, on HIV-1 disease progres-
sion and to a more limited extent HIV-1 adult transmission
[11,12,13,14,15,16,17,18,19]. Although these genetic association
studies suggest a role for KIR-HLA interactions in the control of
HIV infection, they tend to disagree on the exact nature of these
associations. The KIR receptors that seem to be consistently
highlighted as key players however, are KIR3DS1, KIR3DL1 and
to some extent KIR2DL3. These studies have mostly addressed
associations with disease progression among individuals who are
already infected with HIV and the role of these genotypes in
protection against infection in the first place has not been
established. These studies also mostly include populations in the
U.S. and Europe and have not as extensively interrogated
associations among sub-Saharan African populations who are
the people most affected by the HIV epidemic. In recent studies
conducted in our laboratory, unusual robust NK cell responses to
HIV-1 peptides were significantly associated with reduced
maternal-infant HIV-1 transmission and were also associated with
control of HIV-infection in the mothers [3,4]. The role of KIR
and HLA in the context of maternal-infant HIV-1 transmission
has not been previously investigated. Here we describe the KIR
and HLA gene content among several mother-infant HIV-1
cohorts, in order to investigate if KIR genes and/or KIR genes
together with their known HLA ligands may play a role in
susceptibility of infants to HIV-1 infection and/or in modulating
the risk of maternal HIV-1 transmission to the infant. Significant
KIR-HLA associations identified in the current study, particularly
involving KIR2DL2, KIR2DL3 and HLA-C, support a role for NK
cells in both maternal HIV-1 transmissibility and infant HIV-1
susceptibility.
Results
KIR genes/haplotypes/genotypes
KIR genes. All 14 KIR genes and the two pseudogenes were
determined in both the mother and infant groups. The frequencies
of the individual KIR genes/pseudogenes in the various subgroups
within the mothers and infants, as well as the frequency
comparisons between groups, are shown in supplementary
Tables S1 and S2 respectively. There were no significant
differences in comparisons of these frequencies within the
mothers or infant groups. The frequencies of the respective
genes found in this cohort were well within the range of
frequencies reported for other sub-Saharan African countries
[20]. Comparison of gene number (total, activating and inhibitory)
and gene ratio (inhibitory to activating genes) (Table 1) revealed
IU-transmitting mothers to have a trend towards lower total gene
numbers compared to NT mothers (P=0.06). This seemed to be
largely contributed by the inhibitory KIR genes, since IU-
transmitting mothers had a significantly lower number of
inhibitory genes compared to NT mothers (P=0.04). These two
associations were significant post maternal viral load (MVL)
adjustment (gene number: P=0.027; OR=0.73, inhibitory genes:
P=0.033; OR=0.51) but did not seem to be influenced by
stratification into low and high MVL groups (Table 2). Infants
showed no significant differences in gene number and ratio
(Table 1).
In the NVP-stratified group comparisons, no significant
associations were seen in either mothers and infants when
individual KIR genes, or KIR gene number (total, inhibitory,
activating) and ratios (inhibitory:acitivating) were compared (data
not shown).
Haplotypes/Genotypes. Representation of AA and Bx
haplotypes within the mother and infant groups can be seen in
Figure 1a. The ratio of AA haplotype:Bx haplotype groups ranged
from 1:2 to 1:2.6 across groups (i.e. at least double Bx haplotype
representation compared to the AA haplotype), except for the IU-
transmitting mothers, where the ratio of AA:Bx haplotype groups
was 1:1.3. Comparisons of IU and NT mothers with respect to AA
and Bx haplotype groups, however, were not significant (ORs of
Table 1. Mann-Whitney U test comparisons of KIR gene numbers and ratios in the mother and infant groups.
Mann-Whitney U test comparison Mothers
Median (range) P
TR IP IU NT TR vs NT IP vs NT IU vs NT
Total gene number 12 (7–16) 12 (9–16) 10 (7–14) 12 (9–16) 0.72 0.87 0.06
Activating genes 3 (1–6) 3 (1–6) 2 (1–5) 3 (1–6) 0.61 0.63 0.15
Inhibitory genes 7 (4–8) 7 (6–8) 6 (4–8) 7 (6–8) 0.12 0.19 0.04
Ratio: inhibitory to activating genes 2.7 (1.2–6) 2.7 (1.2–6) 3.5 (1.3–6) 2.7 (1.2–6) 0.39 0.42 0.27
Mann-Whitney U test comparison Infants
Median (range) P
INF IP IU EU INF vs EU IP vs EU IU vs EU
Total gene number 12 (7–16) 11.5 (7–14) 12 (9–16) 12 (8–16) 0.74 0.76 0.54
Activating genes 3 (1–6) 2 (1–4) 3 (1–6) 3 (1–6) 0.60 0.51 0.98
Inhibitory genes 7 (5–8) 7 (5–8) 7 (5–8) 7 (5–8) 0.94 0.92 0.43
Ratio: inhibitory to activating genes 2.7 (1.2–7) 3.3 (1.8–7) 2.7 (1.3–6) 2.7 (1.2–6) 0.59 0.37 0.79
Bold P values indicate trends (0.05,P,0.1) or significant differences (P,0.05).
doi:10.1371/journal.pone.0016541.t001
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broader haplotype groups with respect to KIR gene content
(genotypes) for the mother and infant groups is shown in Figure 1b.
Although the IP and IU mother and corresponding infant groups
were also compared, only the broader groups are depicted in
Figure 1b. Thirty-three different genotypes were detected in the
mothers and 35 in the infant group, with a total of 46 different
genotypes detected in the combined mother-infant group. Two
previously unreported (http://www.allelefrequencies.net [20])
genotypes comprised of 7 (AA?) and 10 (Bx?) KIR genes were
detected in a single INF infant, and an NT mother and EU infant
respectively. The genes involved in these two ‘new’ KIR genotypes
are shown in Figure 1c. These ‘new’ genotypes are only putative at
this stage and would need to be verified in order for official
acceptance as new genotypes. The AA1 genotype was the most
highly represented genotype in both the mother and infant groups.
The Bx genotypes, Bx5 and Bx21, were the most highly
represented genotypes in both the mother and infant groups.
Transmitting mothers had significantly lower representation of
Bx20 compared to NT mothers (1.35% vs. 10%; P=0.02;
OR=0.1) and TR mothers had significantly higher representation
of Bx32 compared to NT mothers (5.4% vs. 0.7%; P=0.04;
OR=8.5). This relationship was more pronounced when IP
mothers were compared to NT mothers where IP mothers had
Table 2. Summary of all key associations with adjustments made for maternal viral load.
Genotypic feature
Relationship
between groups
Deleterious (D) or
Advantageous (A) OR P
MVL
Adjusted
OR
MVL
Adjusted
P
OR if
MVL
low
OR if
MVL
high
P if
significant*
Total group comparisons
Mothers
Total KIR gene Number IU , NT A 0.76
a 0.03
a 0.73 0.027 0.68 0.77
KIR inhibitory genes IU , NT A 0.54
a 0.02
a 0.51 0.033 0.52 0.56
Bx20 KIR genotype TR , NT A 0.12 0.02 0.17 0.09 UD 0.385
KIR2DL2/KIR2DL3 TR , NT A 0.53 0.044 0.55 0.066 0.31* 0.74 0.04
KIR2DL2/KIR2DL3 IP , NT A 0.29 0.008 0.32 0.036 0.133 0.43
Bx32 KIR genotype TR . NT D 8.50 0.04 8.98 0.097 UD 2.45
Bx32 KIR genotype IP . NT D 17.2 0.014 27.3 0.011 UD 3.38
KIR2DL3/KIR2DL3 IP . NT D 2.42 0.034 2.70 0.033 6.72* 1.71 0.03
KIR2DS2+C1C1 TR . NT D 2.45 0.074 1.79 0.293 6.97* 0.996 0.04
KIR2DL2/KIR2DL2+C1C1 TR . NT D 5.36 0.041 3.55 0.178 UD 1.85
KIR2DL3/KIR2DL3+C1C2 IP . NT D 3.63 0.010 3.26 0.027 11.83* 1.26 0.002
Infants
KIR3DL1+Bw480I IP , EU A 0.41 0.062 0.51 0.17 0.17 0.75
KIR2DL2/KIR2DL2 IP , EU A 0.16 0.052 0.13 0.058 UD 0.24
KIR2DL3+C1 INF , EU A 0.58 0.062 0.47 0.02 0.30* 0.59 0.03
KIR2DL3/KIR2DL3+C1C2 INF , EU A 0.40 0.038 0.25 0.009 0.19 0.32
KIR2DL3/KIR2DL3+C2C2 IP . EU D 2.87 0.086 5.57 0.008 5.18* 3.64 0.05
NVP stratified group comparisons
Mothers
Bx20 KIR genotype TR , NT: MNVP A 0.00 0.03 UD UD UD UD
KIR2DL2/KIR2DL3 TR , NT: MNVP A 0.49 0.08 0.40 0.039 0.18* 0.73 0.04
KIR2DL2/KIR2DL3 IP , NT: MNVP A 0.14 0.04 0.14 0.08 0.27 UD
Bx32 KIR genotype TR . NT: noMNVP D 7.29 0.09 15.4 0.046 UD 1.22
KIR2DL3/KIR2DL3+C2C2 TR . NT: MNVP D 2.55 0.07 2.49 0.074 2.93 2.45
Infants
KIR2DL3/KIR2DL3+C1C2 INF , EU: MNVP A 0.29 0.03 0.22 0.021 0.24 0.19
KIR2DL3+C1 INF , EU: MNVP A 0.32 0.007 0.29 0.004 0.15* 0.52 0.007
KIR2DL3/KIR2DL3+C2C2 INF . EU: noMNVP D 5.10 0.07 6.16 0.072 23.8* 1.91 0.03
KIR2DL2/KIR2DL2 INF . EU: MNVP D 2.33 0.08 1.90 0.211 4.54* 0.98 0.06
KIR2DL2/KIR2DL2+C1C2 INF . EU: MNVP D 4.46 0.06 3.51 0.116 8.00 2.05
KIR2DL3/KIR2DL3+C2C2 INF . EU: MNVP D 2.21 0.16 3.64 0.033 2.61 3.54
KIR2DL3/KIR2DL3+C2C2 IP . EU: noMNVP D 8.50 0.02 10.42 0.02 48* 4.2 0.02
a: Odds Ratios and P values are from logistic regression analysis; UD: undetermined due to insufficient data points.
MVL: Maternal viral load; NVP: Nevirapine; MNVP: Maternal nevirapine; noMNVP: No maternal nevirapine.
NT: Non-transmitting TR: Transmitting; INF: Infected; EU: Exposed uninfected; IP: Intrapartum; IU: Intrauterine.
doi:10.1371/journal.pone.0016541.t002
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mothers (P=0.014; OR=17.2). Upon correction for MVL, Bx20
only showed a trend (P=0.09; OR=0.17) of lower representation
in TR mothers vs. NT mothers (Table 2), however maternal
nevirapine (NVP) stratification (Table 3) revealed Bx20 to
maintain significant lower representation in TR mothers vs. NT
mothers in the group of mothers that received single dose NVP
(P=0.03; OR=0.00). Bx32 maintained significant high represen-
tation in IP mothers vs NT mothers post MVL correction (Table 2:
P=0.01; OR=27.3) and although only a trend (P=0.09;
OR=7.29) of high representation in TR mothers vs. NT mothers
was seen upon stratification in the group of mothers that did not
receive NVP (noMNVP) (Table 3), this was significant post MVL
correction for this subgroup (Table 2: P=0.046; OR=15.4). The
genes making up genotypes Bx32 and Bx20 are also shown in
Figure 1c. No significant differences with respect to KIR genotypes
were seen in the infants.
KIR-HLA associations
Hardy-Weinberg Equilibrium. No significant deviations
from Hardy-Weinberg proportions were noted for either HLA-B
or HLA-C in both the infant and mother groups (all P’s.0.1).
KIR-HLA-B. Since KIR3DL1 and KIR3DS1 segregate as
alleles of the same locus and are both thought to encode for
receptors that bind HLA-Bw4 ligands, comparisons across the
mother and infant groups involved looking at the dose of KIR and
Bw alleles independently as well as various combinations of KIR-
HLA. The results of these comparisons in the mothers and infants
can be found in Supplementary Tables S3 and S4, respectively.
No significant differences were seen with either the mother or the
infant groups with respect to these alleles and KIR-HLA
combinations. A trend however was noted in the infant group
where IP infants had approximately 20% lower representation of
KIR3DL1+Bw480Ile compared to EU infants (P=0.062;
OR=0.41) (Table S4), however this trend was lost post MVL
adjustment (Table 2) and upon NVP stratification (data not
shown).
KIR-HLA-C: Mothers. Similarly, as for KIR3DL1 and
KIR3DS1, KIR2DL2 and KIR2DL3 segregate as alleles of the
same locus, thus comparisons involved looking at the allelic dose of
these genes and their respective HLA-C allotypes as well as the
KIR-HLA combinations. Results for the overall group mother
comparisons are shown in Table 4.
KIR2DL2/KIR2DL3. TR mothers had significantly lower
representation of KIR2DL2/KIR2DL3 than NT mothers
(P=0.044; OR=0.53), which seems to be largely contributed by
the IP transmitting mothers that have considerably less
representation of this KIR allele combination compared to NT
mothers (P=0.008; OR=0.29). TR mothers maintained this
significant lower representation of KIR2DL2/KIR2DL3 only in the
Figure 1. KIR gene haplotypes and genotypes. a: KIR gene haplotype (AA and Bx) representation in mother and infant groups. b: KIR genotype
representation in mothers and infants. P values for the significant differences between groups are shown. c: Individual KIR genes making up the two
genotypes (Bx20 and Bx32) showing significance in mothers (b) and KIR genes involved in the two putative newly identified genotypes in the current
study population [designated as AA?(7) and Bx?(10)].
doi:10.1371/journal.pone.0016541.g001
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trend in the overall MVL adjustment (Table 2: P=0.066;
OR=0.55) while IP mothers maintained significance post MVL
correction (Table 2: P=0.036; OR=0.32). Stratification
according to NVP showed the TR and IP mothers that received
single dose NVP to have a trend (P=0.08; OR=0.49) and
significant (P=0.04; OR=0.14) lower representation of
KIR2DL2/KIR2DL3 compared to NT mothers, respectively
(Table 3), and, when these subgroups were corrected for MVL
(Table 2), TR mothers maintained significant lower representation
(P=0.039; OR=0.40) and also when stratified into the low MVL
group (P=0.04; OR=0.18), while IP mothers only showed a
trend post MVL correction (P=0.08; OR=0.14).
KIR2DL3/KIR2DL3 and KIR2DL3/KIR2DL3+C1C2. IP
mothers had significantly higher representation of homozygous
KIR2DL3 compared to NT mothers (P=0.034; OR=2.42).
Furthermore, homozygosity for KIR2DL3 in combination with
heterozygosity for HLA-C allotype group (C1C2) was also present in
IP mothers in significantly greater proportion compared to NT
mothers (P=0.01; OR=3.63). Although both these significant
associations were lost upon stratification according to NVP dose
(Table 3), correction for MVL in the overall groups revealed that
both remained significant post correction (Table 2: KIR2DL3/
KIR2DL3 P=0.033; OR=2.70, KIR2DL3/KIR2DL3+C1C2 P=
0.027; OR=3.26) and furthermore stratification into low and high
MVL groups showed both to be significant in the context of low
MVL (Table 2: KIR2DL3/KIR2DL3 P=0.03; OR=6.72,
KIR2DL3/KIR2DL3+C1C2 P=0.002; OR=11.83).
KIR2DL2/KIR2DL2+C1C1. Homozygosity for KIR2DL2
plus homozygosity for its ligand (C1C1) was significantly elevated
in TR mothers compared to NT mothers (P=0.041; OR=5.36),
this significance was however lost upon NVP stratification (Table 3)
and post MVL adjustment (Table 2).
KIR2DS2+C1C1. The trend (P=0.074; OR=2.45) of higher
representation of KIR2DS2 together with homozygosity for its
ligand (C1C1) in TR mothers compared to NT mothers was not
present post NVP stratification or MVL adjustment, but did prove
to be significantly elevated in TR mothers in the context of low
MVL (Table 2: P=0.04; OR=6.97).
KIR-HLA-C: Infants. Results for the overall group infant
comparisons are shown in Table 5.
KIR2DL2/KIR2DL2. IP infants had a strong trend of lower
representation of homozygous KIR2DL2 compared to EU infants
(P=0.052; OR=0.16), and this trend was maintained post MVL
adjustment (Table 2: P=0.058; OR=0.13). Although this trend
was not seen post NVP stratification (Table 3), within the mothers
that received a single dose NVP, KIR2DL2/KIR2DL2 showed an
opposite deleterious trend of higher representation amongst INF
infants compared to EU infants (P=0.08; OR=2.33), which again
showed a trend when analysed in the context of low MVL (Table 2:
P=0.06; OR=4.54).
KIR2DL2/KIR2DL2+C1C2. Although this combination did
not show any significant association in the overall group
comparisons, stratification according to NVP dose showed a
trend (P=0.06; OR=4.46) of high representation in INF infants
compared to EU infants in the group whose mothers received a
Table 3. Summary of key associations in mother and infant groups according to maternal single dose nevirapine.
Key associations
Association
a in
overall group
Association
a in NVP-
stratified group No maternal NVP Maternal NVP
Mothers OR 95% CI P OR 95% CI P
TR (24) vs NT (52) TR (42) vs NT (82)
KIR2DL3/KIR2DL3 + C2C2 NS T: TR . NT (D) 1.48 0.23–9.52 0.65 2.55 0.98–6.63 0.07
Bx20 KIR genotype S: TR , NT (A) S: SA
b 0.40 0.05–3.70 0.66 0.00 0.00-NaN 0.03
KIR2DL2/KIR2DL3 S: TR , NT (A) T: SA 0.55 0.21–1.50 0.32 0.49 0.22–1.08 0.08
Bx32 KIR genotype S: TR . NT (D) T: SA 7.29 0.72–74.11 0.09 ‘ NaN-‘ 0.34
KIR2DL2/KIR2DL2 + C1C1 S: TR . NT (D) - ‘ NaN-‘ 0.32 3.08 0.49–19.18 0.34
IP (16) vs NT (52) IP (10) vs NT (82)
KIR2DL2/KIR2DL3 S: IP , NT (A) S: SA 0.42 0.13–1.38 0.17 0.14 0.02–1.12 0.04
KIR2DL3/KIR2DL3 S: IP . NT (D) - 2.25 0.72–7.06 0.23 2.41 0.64–9.12 0.28
KIR2DL3/KIR2DL3 + C1C2 S: IP . NT (D) - 2.52 0.74–8.58 0.18 2.31 0.42–12.82 0.30
Infants OR 95% CI P OR 95% CI P
INF (24) vs EU (53) INF (41) vs EU (81)
KIR2DL2/KIR2DL2 + C1C2 NS T: INF . EU (D) 0.29 0.03–2.46 0.42 4.46 1.05–18.85 0.06
KIR2DL3/KIR2DL3 + C1C2 S: INF , EU (A) S: SA 0.51 0.10–2.61 0.72 0.29 0.09–0.91 0.03
KIR2DL3 + C1 T: INF , EU (A) S: SA 0.85 0.32–2.27 0.80 0.32 0.15–0.71 0.007
KIR2DL2/KIR2DL2 T: IP , EU (A) T: INF . EU (D) 0.25 0.05–1.22 0.13 2.33 0.91–5.97 0.08
KIR2DL3/KIR2DL3 + C2C2 T: IP . EU (D) T: INF . EU (D) 5.10 0.86–30.07 0.07 2.21 0.76–6.40 0.16
IP (16) vs EU (53) IP (10) vs EU (81)
KIR2DL2/KIR2DL2 T: IP , EU (A) - 0.19 0.02–1.54 0.16 0.00 0.00- NaN 0.60
KIR2DL3/KIR2DL3 + C2C2 T: IP . EU (D) S: SA 8.50 1.39–51.95 0.02 2.28 0.41–12.65 0.30
aS: significant association (P,0.05); T: trend (0.05,P,0.1); NS: Not significant; A: Advantageous; D: Deleterious.
bSA: Same association i.e. the trend or significant association is going in the same direction as non-stratified group comparison.
-: Not applicable (i.e. not significant or no trend in stratified groups).
doi:10.1371/journal.pone.0016541.t003
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adjustment for MVL (Table 2).
KIR2DL3+C1 and KIR2DL3/KIR2DL3+C1C2. The INF
infants had a trend towards lower representation of the
combination of KIR2DL3 and C1 group HLA-C ligand compared
to EU infants (P=0.062; OR=0.58). This was significant (P=0.02;
OR=0.47) post MVL adjustment and also proved to be significant
(P=0.03; OR=0.30) in the context of low MVL (Table 2). Upon
stratification according to NVP dose, it was the INF infants born to
mothers who received a single dose NVP that showed significant
(P=0.007; OR=0.32) lower representation of this combination
compared to the EU infants (Table 3), and again the significance
was maintained post MVL adjustment (Table 2: P=004;
OR=0.29) and in the context of low MVL (Table 2: P=0.007;
OR=0.15) in this NVP-stratified subgroup.
The INF infant group also had significantly lower representa-
tion of the combination of homozygous KIR2DL3 and heterozy-
gous HLA-C allotype group i.e. C1C2 (P=0.038; OR=0.40). This
proved to be more significant post MVL adjustment (Table 2:
P=0.009; OR=0.25) and was also significant upon NVP
stratification in the group whose mothers received single dose
NVP pre- (Table 3: P=0.03; OR=0.29) and post MVL
adjustment (Table 2: P=0.021; OR=0.22).
KIR2DL3/KIR2DL3+C2C2. A weak trend of increased
representation of homozygous KIR2DL3 in the absence of its’
HLA-C ligand (i.e. homozygous C2 group) in the IP infants
compared to the EU infants was noted (P=0.086; OR=2.87).
This proved to be significant (P=0.008; OR=5.57) post MVL
adjustment and also significant (P=0.05; OR=5.18) in the
context of low MVL (Table 2). Stratification according to NVP
dose showed this genotypic combination to be significantly
(P=0.02; OR=8.50) elevated in the IP infants vs. EU infants
whose mothers did not receive NVP (Table 3), and this too
withstood MVL adjustment (Table 2: P=0.02; OR=10.42) and
proved to be significant (P=0.02; OR=48) in the context of low
MVL (Table 2). In addition a trend (P=0.07; OR=5.10) of INF
infants having higher representation of KIR2DL3/KIR2DL3+C2C2
vs. EU infants post NVP stratification in the no maternal NVP
subgroup was noted. When this subgroup was subjected to MVL
adjustment, the trend was maintained (P=0.072; OR=6.16) and
was significant (P=0.03; OR=23.8) in the context of low MVL
(Table 2), however it also proved to be significantly elevated in
INF infants vs. EU infants (P=0.033; OR=3.64) post MVL
adjustment in the infant group whose mothers did receive a single
dose NVP (Table 2).
KIR2DL3/KIR2DL3+C1C2. The genotype KIR2DL3/KIR2-
DL3+C1C2 appears to have conflicting associations, i.e. associated
with a higher chance of IP transmission in the mothers but an
overall decreased susceptibility in the infants. We thus looked at
the genotypes of matching mothers and infants to try and further
elucidate the effect of KIR2DL3/KIR2DL3+C1C2 in both
transmission and susceptibility. These results are depicted in
Figure 2 and show that in the mothers, irrespective of
transmissibility (i.e. whether they are NT, TR or IP-transmitting
mothers), approximately two thirds of all mothers harbouring the
genotype are discordant with their infants for the genotype (i.e.
mother positive for genotype and corresponding infant negative
for genotype) compared to a third that are concordant (both
mother and corresponding infant are positive for the genotype).
In the infants however, the EU infants are distinctly different
to the INF and IP infants with 84% of EU infants that harbour
the genotype being discordant with their mothers and 16%
being concordant. Among INF infants that harbour the genotype
on the other hand, 57% are concordant with their mothers and
43% are discordant and among IP infants, all four IP infants
positive for KIR2DL3/KIR2DL3+C1C2, are concordant with their
mothers.
The effect of HLA alone
Although the aim of this study was not to determine the role of
HLA in maternal-infant HIV-1 transmission, since HLA has been
shown in numerous previous studies to impact strongly on HIV-1
disease progression and to some extent on maternal-infant
transmission, we conducted some preliminary analyses to
determine if the effects we have detected for KIR-HLA are
independent from the effects of HLA alone. Mother-infant HLA
Figure 2. Maternal-infant concordance and discordance with respect to KIR2DL3/KIR2DL3+C1C2.a : Percentage of mother subgroups (all
harbouring KIR2DL3/KIR2DL3+C1C2) that are concordant (M+I+) and discordant (M+I-) with their respective infants for the KIR2DL3/KIR2DL3+C1C2
genotype. M: Mother; I: Infant; +: positive; -: negative; NT: non-transmitting mothers; T: total transmitting mothers; IP: intrapartum-transmitting
mothers. b: Percentage of infant subgroups (all harbouring KIR2DL3/KIR2DL3+C1C2) that are concordant (I+M+) and discordant (I+M-) with their
respective mothers for the KIR2DL3/KIR2DL3+C1C2 genotype. EU: exposed-unifected infants; INF: total infected infants; IP: infants infected through the
intrapartum route.
doi:10.1371/journal.pone.0016541.g002
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HLA-C* alleles and previously defined protective alleles [21] were
investigated and results are shown in Table 6. No significant
differences were detected when comparing mother-infant HLA-B
and/or HLA-C allelic concordance, and, HLA homozygosity in
the mothers did not show any significant associations with
transmission (Table 6). Homozygosity in the HLA-B* locus showed
a trend (P=0.05; OR=3.97) of higher representation in IP infants
compared to EU infants (Table 6) and when comparing individual
alleles, again only the HLA-B* locus appeared to be exerting an
effect with B*08:01 showing a trend (P=0.06; OR=0.30) of lower
representation in INF infants compared to EU infants, B*14:02
showing significantly (P=0.03; OR=‘) higher representation in
TR mothers compared to NT mothers and B*42:01 showing a
trend (P=0.08; OR=0.44) of lower representation in TR mothers
compared to NT mothers (Table 6). No significant associations
were seen with individual HLA-C* alleles. Looking at the
combined effect of previously defined protective alleles (which
again are all HLA-B* alleles), some protective effect seems to be
exerted only in the context of IU transmission, where IU mothers
showed a trend (P=0.05; OR=0.15) and significant (P=0.04;
OR=0.15) lower representation of protective alleles compared to
EU mothers when analysing the genotypic and allelic contribu-
tions, respectively (Table 6).
Discussion
This study was conducted in order to investigate the role of
KIR-HLA in maternal-to-infant HIV-1 transmission. This model
of transmission allows one to determine influence at both the level
of infant susceptibility as well as maternal transmissibility. By
comparing mothers who transmitted to the mothers who did not
transmit HIV-1, a possible role of KIR2DL2 was indicated. The
two KIR genotypes Bx32 and Bx20 showed opposing effects on
transmission with Bx32 having significantly higher representation
in TR mothers compared to NT mothers, which appears to be
largely contributed by the IP-transmitting mothers (Figure 1b) and
although the TR vs. NT association was weakened with MVL
adjustment, the IP vs. NT association was more significant post-
adjustment (Table 2). Bx20 on the other hand, had significantly
higher representation in NT mothers compared to TR mothers
(Figure 1b) and this association was also weakened with MVL
adjustment but showed a similar trend (Table 2). The only
apparent difference between these two genotypes is the absence of
KIR2DL2 in Bx32 (Figure 1C); however they may very well vary in
the composition of the two parental haplotypes making up the
combined genotype. In addition, NT mothers had higher
representation of KIR2DL2 compared to TR mothers which
appears to be independent of whether transmission was IP or IU
Table 6. Comparison of mother and infant groups with respect to HLA concordance, homozygosity, allele frequency and
protective alleles.
HLA Comparison Mothers
a Infants
b
TR vs. NT IP vs. NT IU vs. NT INF vs. EU IP vs. EU IU vs. EU
OR P OR P OR P OR P OR P OR P
Concordance HLA-
B* 0.90 1.00 0.71 1.00 1.09 1.00 ------
C* 0.63 0.32 0.60 0.58 0.59 0.74 ------
B* and C* 0.59 0.43 0.77 1.00 0.00 0.37 ------
B* or C* 0.76 0.56 0.57 0.58 1.26 0.75 ------
Homozygosity HLA-
B* 0.82 1.00 1.68 0.43 0.74 1.00 1.83 0.33 3.97 0.05 0.00 1.00
C* 0.95 1.00 0.94 1.00 0.82 1.00 1.13 0.81 1.26 0.72 0.55 1.00
B* and C* 0.34 0.43 0.89 1.00 0.00 1.00 2.16 0.59 2.72 0.41 0.00 1.00
B* or C* 1.07 0.84 1.34 0.57 1.02 1.00 1.27 0.66 2.12 0.21 0.41 0.70
Alleles
c HLA-
B*08:01 0.74 0.55 ND ND ND ND 0.30 0.06 ND ND ND ND
B*14:02 ‘ 0.03 ND ND ND ND 1.41 0.66 ND ND ND ND
B*42:01 0.44 0.08 ND ND ND ND 0.56 0.30 ND ND ND ND
Protective alleles
d
Genotypic 0.57 0.13 0.59 0.36 0.15 0.05 0.60 0.23 0.49 0.24 0.73 0.78
Allelic 0.54 0.07 0.56 0.30 0.15 0.04 0.67 0.27 0.65 0.51 0.74 0.80
a: TR (Transmitting mothers; N=68–74); NT (Non-transmitting mothers; N=143–150); IP (Intrapartum-transmitting mothers; N=28–29); IU (Intrauterine-transmitting
mothers; N=19–21).
b: INF (Total infected infants; N=70–72); EU (Exposed-uninfected infants; N=149); IP (Intrapartum-infected infants; N=28); IU (Intrauterine-infected infants; N=20).
c: Results are shown only for alleles where trends or significant differences were noted in either group (i.e. mothers and/or infants).
d: Protective alleles are HLA-B*57:02, HLA-B*57:03, HLA-B*58:01 and HLA-B*81:01. In the genotypic comparisons the individual was scored once for possession of at least
one protective allele.
(i.e. if homozygous for protective allele was only scored once) and denominator was the number of individuals. In the allelic comparisons the number of alleles were
scored and the denominator would be the total number of alleles (i.e. accounts for allelic dose of a protective allele).
-: Not applicable since concordance looks at mother-infant pairs.
ND: Not determined.
Bold P values indicate trends (0.05,P,0.1) or significant differences (P,0.05).
doi:10.1371/journal.pone.0016541.t006
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KIR2DL3 was also significantly elevated in NT mothers compared
to TR mothers and most pronounced when restricted to IP-
transmitting mothers (Table 4), with both these associations
withstanding MVL adjustments (Table 2). Combination of
KIR2DL2 homozygosity (KIR2DL2/KIR2DL2) and homozygosity
for its HLA-C ligand (C1C1) however was significantly higher in
TR mothers compared to NT mothers (Table 4), although this
significance was lost upon MVL adjustment (Table 2) suggesting
that viral load may be skewing the effect seen for this KIR-HLA
combination. The data indicate a possible role for KIR2DL2, when
found in heterozygous combination with KIR2DL3, with those
mothers being less likely to transmit through the intrapartum
route. The only reported study [16] involving a role for KIR2DL2
in HIV-1 transmission found significantly higher frequencies of
KIR2DL2 in exposed seronegative African sex workers compared
to seropositive sex workers (P=0.004) as well as significantly more
KIR2DL2/KIR2DL3 heterozygosity among exposed seronegative
sex workers compared to seropositive sex workers (P=0.028;
OR=4.88). These associations are thus similar to the associations
seen in our study, despite the different modes of transmission.
The other KIR gene that appears to be playing a role in
maternal transmission of HIV-1 is KIR2DL3, where homozygosity
for this gene was significantly more highly represented in IP-
transmitting mothers compared to NT mothers and KIR2DL3
homozygosity in the presence of C1C2 heterozygosity was
significantly elevated in IP-transmitting mothers compared to
NT mothers (Table 4). These two relationships remained
significant post MVL adjustment and in addition proved to be
significant in the context of low MVL (Table 2), suggesting that
high viral load may be masking the effect of the genes.
Interestingly, KIR2DL3 and HLA-C1 have also been shown to
play a role in the resolution of hepatitis C virus (HCV) in the
context of low infectious doses of HCV but not in individuals with
high-dose exposure [22]. Jennes et al. [16] also report seropositive
sex workers to show markedly higher proportion of KIR2DL3
homozygosity (P=0.004; OR=0.11) and KIR2DL3 homozygosity
in the presence of C1C2 heterozygosity (P=0.015; OR=0.13)
when compared to exposed seronegative sex workers. Although
the current study and the Jennes et al. [16] study seem to correlate
with regard to the KIR genes and KIR-HLA combinations that
show significant associations, the actual mechanisms that may be
at play remain elusive. Jennes et al. [16] also report and stress the
association of certain inhibitory KIR genes in the absence of their
cognate HLA genes with exposed seronegative status, namely
KIR2DL2/KIR2DL3 in the absence of HLA-C1 and KIR3DL1
homozygosity in the absence of HLA-Bw4, and thus propose that
the absence of HLA ligands for inhibitory KIR may lower the
threshold for activation of NK cells via activating KIR, thereby
resulting in early elimination of HIV-1 infected cells by NK
cytotoxic activity. These associations however were not seen in our
study.
Most of the significant associations seen in maternal HIV-1
transmission were pertaining to the intraparum route, however
IU-transmitting mothers overall had a higher representation of the
AA haplotype group and lower representation of the Bx haplotype
group (more activating genes) when compared to the other
maternal groups (Fig. 1a), suggesting that a more inhibitory NK
cell effector function increases likelihood of intrauterine transmis-
sion. IU-transmitting mothers had a trend of lower total KIR gene
number and significantly lower number of inhibitory KIR genes
compared to NT mothers (Table 1), in agreement with the high
AA haplotype group representation. Overall, fewer genes could
imply overall less immune activation which may be more
conducive to intrauterine transmission and it could very well be
the balance or ratio of select inhibitory KIR to activating KIR genes
which is playing a role rather than a predominance of one or the
other. The significant associations of lower total KIR gene number
and inhibitory KIR genes in the IU-transmitting mothers vs. NT
mothers were maintained post-MVL adjustment (Table 2).
A comparison of infants that become infected with HIV-1 to
those that are exposed but remain uninfected is an ideal model for
investigating the contribution of host genes to increased HIV-1
susceptibility or protection. In this study no significant differences
were observed in the individual KIR gene comparisons, KIR gene
number and ratios or KIR genotype, however the combination of
KIR3DL1 and its HLA-B ligand, Bw480Ile, showed a trend of
higher representation in EU infants compared to IP infants (Table
S4), this trend however was lost upon MVL adjustment (Table 2).
Previous studies have implicated this KIR-HLA combination in
both HIV-1 disease progression [17,19] and risk of HIV-1
infection [13] and interestingly it is the combination of high
expressing KIR3DL1 alleles as well as the cell-retained receptor
expressed by the KIR3DL1*004 allele, in combination with
Bw480Ile (often the HLA-B*57 allele) that confer a strong
protective effect. We failed to see any significant associations with
the KIR3DL1*004 allele+Bw480Ile, however it may be possible
that the trend that was observed could be intensified by comparing
KIR3DL1 high expressing alleles in combination with Bw480Ile
and by selectively looking at the HLA-B*57 expressing individuals
amongst the Bw480Ile group.
Additional trends and significant associations seen within the
infant group again involved KIR2DL2 and KIR2DL3. Homozy-
gosity for KIR2DL2 showed a strong trend for underrepresentation
in IP infants compared to EU infants (Table 5) which was
maintained upon MVL adjustment (Table 2), however no
significant associations were observed with the combination of
this KIR gene and its cognate HLA-C1 ligand. On the other hand
KIR2DL3 in combination with its HLA-C1 ligand showed a trend
of low representation amongst INF infants compared to EU
infants and a combination of homozygosity for KIR2DL3 and
heterozygosity for the HLA-C ligand (C1C2) showed significant
low representation among INF infants compared to EU infants
(Table 5). These associations were strengthened upon MVL
adjustment and KIR2DL3+C1 also proved to be significantly
elevated in EU infants compared to INF infants in the low MVL
group (Table 2), again suggesting that the impact contributed by
genotype is seen under conditions of low viral load and that high
viral load appears to override the effect of host genotype. This
association is opposite to the effect seen of this same combination
in the mothers and by Jennes et al. [16]. To investigate this further
we looked at the level of concordance between mothers and infants
harbouring this genotype, and the results (Figure 2) point to this
genotype being protective in the infant only when there is
discordance i.e. the mother lacking the genotype, and possibly that
the protection is in the context of IP transmission as the three INF
infants (43%) that were discordant for the genotype were all IU-
infected infants.
The trend seen with IP infants having higher representation of
homozygosity for KIR2DL3 and C2 compared to EU infants was
substantially more significant post MVL adjustment and also
appears to be apparent under conditions of low maternal viral load
(Table 2), again highlighting a role for KIR2DL3, in the absence of
its ligand, with increased infant IP-susceptibility to HIV-1.
No significant associations were seen in either the mothers or
the infant group with regard to KIR3DS1 alone or in combination
with its Bw4 ligand, a KIR gene and HLA-KIR combination that
has been studied and reported on widely in relation to HIV-1
KIR-HLA and Maternal-Infant HIV-1 Transmission
PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e16541disease progression in the literature [12,14,15,18,23]. KIR3DS1
however is found at a very low frequency in our study population
(,10%; Tables S1 and S2), and may thus not be contributing a
role that is detectable at a population level.
Antiretroviral drugs play a role in reducing maternal-to-infant
HIV-1 transmission, and given that a previous study has seen the
protective effect of high CCL3L gene copies obscured by the
presence of maternal single dose NVP [24], we analysed our study
population according to maternal NVP dose. Absence of maternal
NVP failed to reveal strong associations that were previously not
there and did not appear to significantly strengthen any
associations already seen in both the mother and infant groups.
Some previously significant differences that were lost are most
likely due to the smaller numbers being compared. Many of the
trends that were strengthened or lost in both the presence and
absence of maternal NVP, were often as a result of the skewing of
the data due to the no maternal NVP mother and infant groups
having a higher proportion of IP mothers and infants respectively
and the maternal NVP mother and infant groups having higher
proportions of IU mothers and infants respectively (see footnote
Table 7). This is not unexpected since administration of NVP at
labour serves to reduce IP infection and thus one would expect a
skewing towards fewer IP transmissions and infections in the group
of mothers that received NVP and visa versa. Some associations
however seemed not to be affected by the skewed data. The Bx20
genotype which was no longer significantly underrepresented in
TR mothers vs. NT mothers in the absence of maternal NVP,
maintained its significance in the presence of maternal NVP. Also,
in the presence of maternal NVP, the trend of low representation
of KIR2DL3 and its C1 ligand in INF infants vs. EU infants, was
shown to be highly significant (P=0.007). This association was
strengthened post MVL adjustment and highly significant in the
context of low MVL (Table 2). KIR2DL3 homozygosity and
heterozygosity for the HLA-C ligand (C1C2), maintained signif-
icant low representation in INF vs. EU infants, only in the
presence of maternal NVP, and was maintained post MVL
adjustment again.
Since it is in the presence of maternal NVP that most of the
associations remained significant or were strengthened, this raises
a number of postulations. Firstly, the possibility that NVP is
lowering MVL, however with administration of NVP at labour, it
is unlikely that the peripheral viral loads would be reduced to the
Table 7. Distribution of study participants (total and maternal nevirapine-stratified groups) according to cohorts previously
described and maternal viral load (VL) and CD4 counts.
Cohorts* Total
VL (copies/ml)
log10 CD4 (cells/ml)
1234
N= N= Median (range)
Median
(range)
Total groups
NT mothers 39 56 14 41 150 3.97 (1.70–5.88)
N=136
450 (16–1655)
N=137
TR mothers 22 25 7 20 74 4.79 (2.60–5.87)
N=66
375 (25–1026)
N=65
EU infants 41 51 17 41 150 - -
INF infants 22 24 6 20 72 - -
Maternal nevirapine (NVP) stratified groups
Maternal NVP
NT mothers 9 35 0 38 82 3.89 (2.60–5.88)
N=82
474 (16–1479)
N=72
TR mothers
a 5 19 0 18 42 4.49 (2.60–5.87)
N=41
390 (25–1011)
N=36
EU infants 9 34 0 38 81 - -
INF infants
c 51 8 01 8 4 1- -
No maternal NVP
NT mothers 30 21 1 0 52 3.92 (1.70–5.69)
N=51
565 (125–
1655)
N=49
TR mothers
b 1 7 6102 44 . 7 3 ( 2 . 92–5.79)
N=23
444 (127–
1026)
N=21
EU infants 32 17 4 0 53 - -
INF infants
d 1 7 6102 4- -
-: Not applicable (EU infants) and not determined (INF infants).
*: Described in Kuhn et al. (2007).
a:10 IPs (43%) + 13 IUs (56%)=23 (known mode of transmission); 19=unknown mode of transmission.
b:16 IPs (69.6%) + 7 IUs (30.4%)=23 (known mode of transmission); 1=unknown mode of transmission.
c:10 IPs (45.5%) + 12 IUs (54.6%)=22 (known infection route); 19=unknown infection route.
d:16 IPs (69.6%) + 7 IUs (30.4%)=23 (known infection route); 1=unknown infection route.
doi:10.1371/journal.pone.0016541.t007
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comparison of MVL between mothers that received NVP to those
that did not (since blood was drawn at labour) showed that there
was no significant difference between the two groups (data not
shown). It is generally considered that it is the exposure of the
infant to maternal NVP, which crosses the placenta, that helps
prevent the establishment of HIV-1 infection in the infant. Thus,
low MVL and exposure to maternal NVP result in a similar
outcome, namely a reduced risk of infant to infection and possibly
the ability for select genotypes to reveal their effect. Lastly, it is
possible that NVP is having a modulatory effect on certain
immune pathways that are somehow enhancing the effects of
select genotypes. Immunomodulatory effects of NVP in infants
born to HIV-1 seropositive mothers have previously been reported
[25]. This study serves to highlight once again that the study of
genes that impact on maternal-to-infant HIV-1 transmission
cannot be done so in the absence of accounting for the presence
of the antiretroviral drugs.
A preliminary investigation into the influence of HLA alone on
mother-to-infant HIV-1 transmission in this cohort and whether
this may be influencing the results of this study, revealed that only
the HLA-B* locus seemed to be exerting some effect (Table 6). In a
previous study where maternal HLA homozygosity and HLA
concordance was linked to increased risk of vertical HIV-1
transmission [26], this was more apparent with IU and breast milk
transmission, and since breast milk transmission was not a factor in
this study and only 21 out of 74 mothers in this study were
confirmed to transmit via the IU route (vs. 29 IP transmissions),
the remaining 24 unknown transmission routes may be predom-
inantly of the IP route. Furthermore, the Mackelprang et al. study
[26] was also carried out on a cohort receiving antenatal
zidovudine which could be influencing transmission in its own
right. Nevertheless, the absence of a contribution of HLA-C* on
mother-to-infant transmission in our study further strengthens the
significant associations seen with KIR and HLA-C*.
Due to the hypothesis-generating nature of this study, rather
than a wide-ranging screening for genes and associations,
correction for multiple testing was not applied. This appears to
be in agreement with other studies that have investigated the role
of KIR-HLA in viral transmission and disease progression [22,24].
Adjustment for multiple comparisons corrects for type 1 errors but
increases the risk of type 2 errors. Given the complexity and
multifactorial nature of maternal-infant HIV-1 transmission, we
considered it more important to identify potential factors that may
play a role in this route of infection rather than simply dismissing
these leads as due to chance variations brought about by multiple
comparisons. Nevertheless, it remains important that the consis-
tency of these associations in other cohorts be investigated.
There are a number of limitations of the current study and areas
that we feel require further investigation to elucidate the exact role
of KIR-HLA on mother-to-infant HIV-1 transmission. Firstly,
although we looked at mother-infant genotype concordance with
respect to KIR2DL3/KIR2DL3+C1C2, this was only conducted in
order to try and understand the apparent contradictory effect of
this particular genotype. However, this has served to highlight the
importance of looking at mother-infant genotypic combinations
with respect to the remaining KIR-HLA combinations. Further-
more, allorecognition of infected maternal cells in the infant may
well contribute to protection from infection, thus analysis of the
infant KIR vs. the corresponding mother’s HLA can serve to
determine if allorecognition is a contributing factor. It is important
to note that this study simply looked at KIR gene content and does
not account for allelic variation or the fact that having a particular
KIR gene does not necessarily equate into expression of that gene
and the presence of that receptor on the cell surface. In addition,
HLA-G serves as a ligand for KIR2DL4 and is thought to play a
role in IU transmission, however, given that most individuals have
the KIR2DL4 gene, this too would need to be addressed at the
allelic level. HLA-G polymorphisms have also been described that
may very well affect KIR-HLA interactions and impact on vertical
transmission.
In conclusion, this study is the first to investigate the role of KIR
and KIR-HLA in HIV-1 maternal-to-infant transmission, and
suggests a role for KIR2DL2, KIR2DL3 with their cognate HLA-C
ligands in HIV-1 transmission and susceptibility in the context of
low maternal viral load and/or maternal nevirapine.
Materials and Methods
Study participants
A total of 224 mothers and 222 infants, recruited as part of 4
mother-to-infant HIV-1 transmission cohorts in Johannesburg,
South Africa, were used in this study. A detailed description of the
4 cohorts is given by Kuhn et al. [24]. All available transmitting
pairs (infant infected) and a random sample of two non-
transmitting pairs (mother infected but infant uninfected) per case
were selected from each cohort using a case-cohort design. Since
complete samples were not available for every pair, of the 446
individuals, 145 were matching mother-infant pairs where the
infants were HIV-1 exposed but remained uninfected (EU), and
there were 5 unmatched mothers and 5 unmatched infants thereby
totalling 150 EU infants and 150 non-transmitting (NT) mothers.
There were 72 matching mother-infant pairs where the infant was
determined HIV-1 infected and two unmatched mothers thereby
totalling 72 infected (INF) infants and 74 transmitting (TR)
mothers. The infant’s infection status was determined by a HIV-1
DNA PCR test (Roche Amplicor version 1.5). Of the 72 INF
infants, 20 were infected in utero (IU; PCR positive at birth), 28
were infected intrapartum (IP; PCR negative at birth, positive at 6
weeks postpartum) and the remaining 24 were found to be infected
at 6 weeks but had no birth sample available for determining the
timing of transmission. In the case of TR mothers, 23% in our
study reported any breastfeeding vs. 16% of NT mothers (not
significant). The average duration of breastfeeding for those who
initiated any breastfeeding was 14 days. By extrapolation the effect
of breastfeeding would be negligible in this cohort. Moreover as
breastfeeding and IP transmission are thought to occur across
mucosal surfaces vs. IU which seems a more direct into the system
exposure, thus, combining the majority IP with a tiny proportion
of breastfeeding would not confound the genetic outcomes with
transmission likelihood.
Since this study aims at investigating the role of select genes on
mother-to-infant HIV-1 transmission, one cannot exclude the role
played by the various antiretroviral drugs administered in the 4
cohorts studied here. In addition to looking at the overall groups,
we stratified the study participants according to whether the
mothers were administered no nevirapine (NVP) or a single-dose
NVP during labour. All infants received a single dose of NVP.
Mothers and infants that were administered other antiretroviral
drugs were excluded from this part of the analysis.
Since not all the individuals described by Kuhn et al. [24] were
used in this study, Table 7 shows the distribution of the study
participants across the 4 cohorts. The median maternal viral loads
(copies/ml) and median CD4 counts (cells/ml) for the broad groups
are also shown in Table 7. The viral load determinations were
done on maternal delivery samples using the Roche Amplicor
RNA Monitor assay version 1.5 (Roche Diagnostic Systems, Inc.,
Branchburg, NJ) and the CD4 T-cell counts were determined
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Dickinson (San Jose, CA).
This study was approved by the University of the Witwaters-
rand Committee for Research on Human Subjects and the
Institutional Review Board of Columbia University and signed
informed consent was obtained from all mothers who participated
in the study.
Genomic DNA extraction
Genomic DNA used for both the KIR as well as the HLA
genotyping was extracted from 5 ml whole blood using the
QIAamp DNA Blood Mini Kit (Qiagen, Dusseldorf, Germany)
according to the manufacturer’s instructions.
KIR genotyping
KIR genotying was performed using sequence-specific primer
(SSP) PCR (Olerup SSP KIR Genotyping kit; Olerup SSP AB,
Sweden). KIR locus typing was carried out to detect the presence
or absence of the following 14 KIR genes: KIR2DL1, KIR2DL2,
KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3,
KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, KIR3DS1,
and 2 pseudogenes: KIR2DP1 and KIR3DP1. The kit also allowed
allelic resolution of KIR3DL1 for detection of KIR3DL1*004.
Group B haplotypes were defined by the presence of one or
more of the following genes: KIR2DL5, KIR2DS1, KIR2DS2,
KIR2DS3, KIR2DS5, and KIR3DS1. Group A haplotypes were
defined by the absence of all group B genes and the presence of
KIR2DL1, KIR2DL3, KIR2DL4, KIR2DS4, KIR2DP1, KIR3DL1,
KIR3DL2, KIR3DL3 and KIR3DP1 (14
th International HLA and
Immunogenetics Workshop, 2005). The group B haplotypes were
collectively termed Bx, since they represent a mixture of AB and
BB haplotypes. Furthermore, KIR genotype profiles were assigned
to the AA and Bx haplotype groups using the New Allele
Frequency Database: http://www.allelefrequencies.net [20].
HLA genotyping
HLA-B and HLA-C high resolution genotying was performed
using a sequence-based typing (SBT) strategy using the protocol
described for heterozygous amplification of exon 2, intron 2, and
exon 3 of the HLA loci [27]. Nucleotide sequencing was
performed on an ABI 3730 Genetic Analyzer using Big Dye
Terminator v1.1 chemistry (Applied Biosystems, Foster City, CA).
Allele assignment was performed using SeqScape v2.5 software
(Applied Biosystems) and a library compiled from the 2.17.0
release of the IMGT/HLA Database.
HLA-B and HLA-C alleles were classified into their respective
allotype groups based on the following: HLA-B molecules express
one of two mutually exclusive epitopes, Bw4 and Bw6 determined
by 5 variable amino acids spanning positions 77-83 [28].
Furthermore the Bw4 epitopes can be divided into two groups,
namely Bw4-80Ile and Bw4-80Thr depending on the presence of
isoleucine or threonine at position 80 respectively [29]. HLA-C
alleles can be divided into two groups, C1 and C2 groups based on
the position of an asparagine or lysine residue at position 80
respectively [30].
Test for Hardy-Weinberg (HLA)
Overall deviations from Hardy-Weinberg proportions for the
HLA-B and HLA-C alleles were tested using the conventional
Monte Carlo exact test of Guo and Thompson (1992) [31]
implemented through the computer program TFPGA (Tools for
Population Genetic Analyses version 1.3; 1997: author Mark. P.
Miller). The mother and infant groups were tested separately.
KIR-HLA Analysis
Frequencies of KIR A and B haplotypes and genotypes, HLA-B
and HLA-C allotype groups, individual KIR genes as well as
combinations of select KIR genes and their known ligands were
determined and compared between the appropriate groups.
KIR2DL2 and KIR2DL3 encode receptors that bind to C1 group
HLA-C molecules. KIR2DL1 binds C2 group HLA-C molecules
and KIR3DL1 binds to Bw4 HLA-B molecules. Several studies
[29,32,33] have shown that Bw4-80Ile molecules serve as better
ligands for KIR3DL1 than Bw4-80Thr molecules. KIR2DS1 and
KIR2DS2 bind to C2 group and C1 group HLA-C allotypes
respectively. Although the ligand for KIR3DS1 is not definitively
known, its high (.95%) amino acid sequence similarity in its
extracellular domain with KIR3DL1, and data showing that the
combination of KIR3DS1-Bw4-80Ile has been associated with
slow progression to AIDS [18], suggest Bw4 molecules as putative
ligands of this receptor.
Fisher’s exact tests were used to calculate statistical significances
and exact 95% confidence intervals (CI) of odds ratios (OR) of
genotype frequency differences (SISA: Simple Interactive Statistical
Analysis; [34]). Two-sided tests were used and the level of
statistical significance for analyses was set at P,0.05. No
adjustment was made for multiple comparisons.
In addition, the contribution of KIR gene number as well as the
balance between activating and inhibitory KIR (ratio of activa-
ting:inhibitory KIR gene number) was compared between groups
by using the non-parametric Mann-Whitney U test (SPSS software
version 15.0; SPSS Inc.).
Multivariable logistic regression was used to adjust for maternal
viral load (MVL) and stratified analyses of the associations
between genotypes and transmission was conducted among
women with high and low MVL defined as being above or below
the median viral load for the study population overall.
The effect of HLA alone
To determine if HLA alone was impacting on maternal-infant
HIV-1 transmission and thereby confounding the results seen with
the KIR-HLA analysis, we investigated the effect of HLA by looking
at the influence of a number or factors, namely:
Maternal-infant HLA concordance. Concordance was
scored as the number of shared HLA-B and HLA-C alleles, HLA-
A data was not available for this cohort and thus could not be
looked at. Mothers and infants share at least one allele at each
locus. We analysed the effect of concordance (two shared alleles) in
each locus separately as well as the effect of combined
concordance (i.e. concordant at both loci) and the effect of
concordance in either locus (i.e. HLA-B or HLA-C concordance).
HLA homozygosity. The effect of maternal and infant
homozygosity at the HLA-B and HLA-C loci was looked at
independently and in addition, the effect of combined
homozygosity (i.e. both loci homozygous) and homozygosity at
one or the other locus (i.e. HLA-C or HLA-B) was investigated.
HLA alleles. The effect of individual HLA-B and HLA-C
alleles on both transmission and infant susceptibility were
investigated by comparing the frequencies of all alleles present in
the respective groups. These comparisons were only carried out on
the broad groups (i.e. TR vs. NT mothers and INF vs. EU infants).
HLA protective alleles. The following alleles have been
previously shown to be associated with low viral loads and high
CD4 counts in a cohort of HIV-I-infected adults in South Africa:
HLA-B*57:02, HLA-B*57:03, HLA-B*58:01 and HLA-B*81:01
[21]. We looked at the combined effect of these alleles on both
transmission and susceptibility by comparing the combined
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genotypic and allelic frequencies were compared.
Fisher’s exact test was used to calculate statistical significances
between the groups above. Correction for MVL and stratification
according to maternal NVP dose were not carried out on the HLA
comparisons and no adjustment was made for multiple comparisons.
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